抄録
Background & Aims : Levofloxacin (LVFX) is a newly synthesized quinolone antibiotic, and although LVFX 500 mg once-daily has been reported to have good efficacy against with respiratory tract infections in the US and other countries, once-daily the regimen seldom been used in Japan. Methods : This randomized, parallel-group, open, multicenter clinical study was designed to compare a 7-day course of LVFX 300 mg once-daily with LVFX 100 mg three-times-daily in elderly patients with respiratory tract infections. Between February 2002 and March 2003, a total of 63 patients with significant respiratory tract infections were enrolled in this study. Results : Data were available for 49 patients. The clinical cure rate was 76.0% (19/25) in the LVFX 300 mg once-daily group and 83.3% (20/24) in the LVFX 100 mg three-times-daily group. The overall clinical cure rates and overall incidences of adverse reactions were similar in both groups. There was also no significant difference in compliance between the groups. Conclusions : LVFX 300 mg once-daily is as effective and safe as LVFX 100 mg three-times-daily in elderly patients with respiratory tract infections.
